Form 4: Sana Bio CFO Wyrick Reports Equity Transactions

Sana Biotechnology's Acting CFO, Susan D. Wyrick, reported routine equity transactions including RSU vesting, option grants, and share dispositions for tax withholding.

Summary

• Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, Inc. (SANA), reported changes in her beneficial ownership.
• Transactions include the acquisition of 10,000 shares of common stock on June 3, 2025, and another 10,000 shares on December 3, 2025, both at a price of $0.00, likely due to RSU vesting.
• Dispositions of 2,567 shares on June 4, 2025, at $2.32 and 2,565 shares on December 4, 2025, at $4.44 occurred, typically for tax withholding related to vesting.
• Acquired 3,400 Restricted Stock Units (RSUs) on December 13, 2024, which vest 100% on December 13, 2025, contingent on continuous service.
• Acquired 5,100 stock options on December 13, 2024, with an exercise price of $1.89, which vest 100% on January 13, 2026, contingent on continuous service and expire on December 12, 2034.
• Beneficial ownership of common stock after these transactions is 178,263 shares.
• The filing also includes shares acquired through Sana's 2021 Employee Stock Purchase Plan (ESPP): 3,000 shares on May 15, 2025, and 3,000 shares on November 14, 2025.
• The transaction dated December 13, 2024, was reported late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation transactions, including grants of new equity and vesting of existing awards, which are generally positive for executive retention and alignment. However, a minor negative is the late reporting of one transaction due to an administrative error.

Positives

• Grant of new Restricted Stock Units (3,400 units) and Stock Options (5,100 options) to a key executive, aligning management incentives with shareholder value.
• Acquisition of shares through the Employee Stock Purchase Plan (ESPP) by the executive, indicating continued investment in the company.

Negatives

• The transaction dated December 13, 2024, was reported late due to an inadvertent administrative error.

Risks

• The vesting of RSUs and stock options is contingent on continuous service, meaning the executive must remain with the company until the specified vesting dates to fully realize these benefits.

Future Outlook

The vesting schedules for RSUs and stock options extend into 2025 and 2026, indicating a continued commitment of the executive to the company's long-term performance.

Industry Context

This filing is a routine disclosure of executive equity compensation and transactions, common across all publicly traded companies, and does not provide specific industry-related insights.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants of RSUs and stock options align the interests of the Acting CFO with shareholders, as her compensation is tied to the company's stock performance.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates a broader program for employee share ownership.

Next Steps

• Susan D. Wyrick's 3,400 Restricted Stock Units are scheduled to vest on December 13, 2025.
• Susan D. Wyrick's 5,100 Stock Options are scheduled to vest on January 13, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including the vesting of restricted stock units, grants of new options and RSUs, and sales for tax purposes. Such transactions are standard and generally do not provide significant new information to warrant a change in investment recommendation. The late reporting of one transaction due to an administrative error is minor. Therefore, a "hold" recommendation is appropriate as this filing does not present a strong catalyst for either buying or selling the stock.

Keywords

Sana Biotechnology, SANA, Form 4, Insider Trading, Equity Transactions, Restricted Stock Units, Stock Options, CFO, Employee Stock Purchase Plan, Executive Compensation